Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Liabilities and Shareholders Equity (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 5.65% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 billion, a 31.0% increase, with the full-year FY2025 number at $1.0 billion, down 5.65% from a year prior.
  • Liabilities and Shareholders Equity was $1.0 billion for Q4 2025 at Janux Therapeutics, down from $1.0 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q4 2024 to a low of $341.5 million in Q2 2023.
  • A 5-year average of $598.4 million and a median of $391.1 million in 2021 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 2242.13% in 2021, then decreased 11.38% in 2023.
  • Janux Therapeutics' Liabilities and Shareholders Equity stood at $379.8 million in 2021, then decreased by 4.16% to $364.0 million in 2022, then increased by 4.5% to $380.4 million in 2023, then skyrocketed by 179.05% to $1.1 billion in 2024, then decreased by 5.65% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for JANX's Liabilities and Shareholders Equity are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).